Li, Hongliang
Guo, Yankai
Deng, Jielin
Gali, Hariprasad
Weedin, Elizabeth A.
Burks, Heather R.
Craig, LaTasha B.
Yu, Xichun http://orcid.org/0000-0001-6760-3410
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (R01HL128393)
Oklahoma Center for the Advancement of Science and Technology (HR17-123)
Article History
Received: 24 August 2021
Accepted: 10 November 2021
First Online: 22 November 2021
Compliance with ethical standards
:
: D.C.K., X.Y., H.L., and L.B.C. hold a US patent (10,975,124) and a US patent application (17/165,070, D.C.K.) regarding the retro-inverso peptides used in this manuscript. All other authors have no conflict of interest to disclose.
: This study was approved by the University of Oklahoma Health Sciences Center Institutional Review Board and conforms to the US Federal Policy for the Protection of Human Subjects.
: Informed consent was obtained from all individual participants included in the study.